SOPHiA GENETICS Unveils New Tool to Monitor Acute Myeloid Leukemia
SOPHiA GENETICS Unveils New Tool to Monitor Acute Myeloid Leukemia
SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company's comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.
SOPHiA GENETICS（納斯達克：SOPH）是一家雲原生醫療科技公司和全球數據驅動醫學領域的領導者，今天宣佈推出新的殘留急性髓細胞白血病（RAM）應用程序。這一新業務擴展了公司全面的腫瘤學產品線，支持可衡量殘留病情的能力，並將於今年夏天在全球範圍內向客戶提供。
Acute Myeloid Leukemia (AML) represents about one percent of all cancers worldwide, yet is one of the most common forms of leukemia in adults1. Over 50 percent of AML patients relapse within 3 years after achieving complete remission2, therefore post-treatment monitoring is imperative for AML patients, particularly within the first two years, to help quickly detect any signs of relapse3. MRD solutions can help inform post-remission therapy and identify early relapse, and serve as a primary endpoint in clinical trials, helping researchers detect even the smallest trace of cancer and support better patient outcomes.
急性髓細胞白血病（AML）佔全球所有癌症的約1％，但是是成人白血病的最常見形式之一。2在完全緩解後3年內，超過50％的AML患者會復發。因此，AML患者的治療後監測至關重要，特別是在前兩年內，以幫助快速檢測出任何復發跡象。MRD解決方案可以幫助了解緩解後治療情況並確定早期復發，並作爲臨床試驗的主要終點，幫助研究人員檢測到甚至是最小的癌症痕跡，支持更好的患者預後。